Dr. Crilley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2 Capital Way
Ste 220
Pennington, NJ 08534Phone+1 609-303-0747Fax+1 609-303-0771
Summary
- Dr. Pamela Crilley is an oncologist in Pennington, NJ and is affiliated with Capital Health Medical Center-Hopewell. She received her medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 38 years. She specializes in breast cancer, genitourinary oncology, and hematologic oncology and is experienced in non-hodgkin lymphoma, breast cancer, genitourinary cancer, myeloproliferative disorders, and hodgkin's lymphoma. She has more than 50 publications and over 500 citings.
Education & Training
- Jefferson Health NortheastResidency, Internal Medicine, 1979 - 1982
- Philadelphia College of Osteopathic MedicineClass of 1979
Certifications & Licensure
- PA State License 1980 - 2026
- NJ State License 2021 - 2025
- IL State License 2013 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
Publications & Presentations
PubMed
- 82 citationsPembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) S...Ajjai Alva, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Damien Hansra
Journal of Clinical Oncology. 2021-04-12 - 34 citationsCetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Pro...Julie Gottlieb Fisher, David Tait, Elizabeth Garrett-Mayer, Susan Halabi, Pam K. Mangat
Targeted Oncology. 2020-10-22 - 36 citationsPalbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K. Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Elie G. Dib
JCO Precision Oncology. 2020-06-25
Press Mentions
- Even During Pandemic, Cancer Screenings Remain VitalOctober 7th, 2020
- People Donate Life-Saving Blood, Bone Marrow at CTCASeptember 30th, 2019
- 16 Things You're Getting Wrong About Cancer, According to ExpertsFebruary 7th, 2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: